Study identification

EU PAS number

EUPAS1000000514

Study ID

1000000514

Official title and acronym

Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066)

DARWIN EU® study

No

Study countries

United States

Study description

This non-interventional, retrospective database analysis will describe treatment outcomes including asthma exacerbations and healthcare resource utilization and costs among severe asthma patients initiating tezepelumab and segmented by payer channel (with a special emphasis on the Medicare FFS population) and by prior biologic experience.
Secondary and exploratory analyses will include a description of patterns of tezepelumab utilization and OCS dosing.

Study status

Ongoing
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen 100%
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable